Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fabry disease: enzyme replacement therapy.

M R Bongiorno1, G Pistone, M Aricò

  • 1Department of Dermatology, University of Palermo, Via del Vespro 131, 90123 Palermo, Italy. istderm@unipa.it

Journal of the European Academy of Dermatology and Venereology : JEADV
|February 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection.

Pathogens and global health·2022
Same author

Our experience with prurigo nodularis treated with dupilumab.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

Response to 'No evidence of SARS-CoV-2 infection by polymerase chain reaction or serology in children with pseudo-chilblain'. Reply from the authors.

The British journal of dermatology·2020
Same author

Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

No evidence of SARS-CoV-2 infection by polymerase chain reaction or serology in children with pseudo-chilblain.

The British journal of dermatology·2020

Enzyme replacement therapy using alpha-galactosidase A safely improved kidney function and neurological symptoms in Fabry disease patients over 12 months. This treatment offers a significant advance for managing this rare genetic disorder.

Area of Science:

  • Biochemistry
  • Genetics
  • Internal Medicine

Background:

  • Fabry disease is an X-linked lysosomal storage disorder caused by alpha-galactosidase A deficiency.
  • This enzyme defect leads to systemic accumulation of specific glycosphingolipids.
  • Clinical presentation of Fabry disease is highly variable.

Purpose of the Study:

  • To evaluate the safety and efficacy of enzyme replacement therapy (ERT) in Fabry disease patients.
  • To assess the impact of ERT on neurological, renal, and cardiac manifestations.

Main Methods:

  • Four hemizygous male patients with Fabry disease received intravenous infusions of purified alpha-galactosidase A.
  • Treatment was administered bi-weekly for 12 months at a dosage of 0.2 mg/kg.
  • Outcomes included assessment of neurological symptoms, kidney function (creatinine clearance), cardiac status, angiokeratomas, and corneal dystrophy.

Related Experiment Videos

Main Results:

  • Enzyme replacement therapy with alpha-galactosidase A was safe and well-tolerated.
  • After 12 months, a significant increase in mean creatinine clearance was observed.
  • Patients showed marked improvement in acroparesthesias and hypohidrosis.

Conclusions:

  • Enzyme replacement therapy with alpha-galactosidase A is a safe and effective treatment for Fabry disease.
  • ERT demonstrates potential to improve renal function and alleviate key symptoms.
  • This therapy represents a significant advancement in improving the prognosis for patients with Fabry disease.